Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 467-468

  Adenis, Antoine ^a   Conroy, Thierry ^b  

^a CENTRE OSCAR LAMBRET   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; HUMAN; LETTER; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58549097877     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6417     Document Type: Letter

References (10)

1. Ajani JA, Winter K, Komaki R, et al: Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 26:4551-4556, 2008
2. Bains MS, Stojadinovic A, Minsky B, et al: A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiovasc Surg 124:270-277, 2002
3. Adelstein DJ, Rice TW, Rybicki LA, et al: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonran-domized comparison with fluorouracil-based therapy. J Clin Oncol 18:2032-2039, 2000
4. al-Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 15:277-284, 1997
5. Conroy T, Yataghene Y, Etienne PL, et al: Definitive chemoradiotherapy (CRT) with folfox 4 or 5FU-cisplatin as first line treatment for patients (pts) with inoperable esophageal cancer (IEC): Final results of a randomized phase II study. J Clin Oncol 25:205s, 2007 (suppl; abstract 4532)
6. Ajani JA, Winter K, Komaki R, et al: Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 26:4551-4556, 2008
7. Bains MS, Stojadinovic A, Minsky B, et al: A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiovasc Surg 124:270-277, 2002
8. Adelstein DJ, Rice TW, Rybicki LA, et al: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonran-domized comparison with fluorouracil-based therapy. J Clin Oncol 18:2032-2039, 2000
9. al-Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 15:277-284, 1997
10. Conroy T, Yataghene Y, Etienne PL, et al: Definitive chemoradiotherapy (CRT) with folfox 4 or 5FU-cisplatin as first line treatment for patients (pts) with inoperable esophageal cancer (IEC): Final results of a randomized phase II study. J Clin Oncol 25:205s, 2007 (suppl; abstract 4532)